ELOX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 14:26):

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases...

Stats
Today's Volume	1 165.00
Average Volume	7 748.00
Market Cap	2.47M
EPS	$0 ( 2024-04-01 )
Next earnings date	( $-1.220 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0900
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-24	Walts Alan Edmund	Buy	7 500	Restricted Stock Units
2024-01-24	Rubin Steven D	Buy	7 500	Restricted Stock Units
2024-01-24	Androski Lindsay	Buy	7 500	Restricted Stock Units
2024-01-24	Aggarwal Sumit	Buy	60 000	Restricted Stock Units
2023-01-30	Walts Alan Edmund	Buy	2 859	Stock Options (Right to Buy)

INSIDER POWER
100.00
Last 94 transactions
Buy: 28 846 630 \| Sell: 836 099

Eloxx Pharmaceuticals Inc Correlation

10 Most Positive Correlations
PAIC	0.954
SVAC	0.941
RMRM	0.917
MTSL	0.873
CASI	0.869
TLGT	0.866
AGMH	0.861
BLKB	0.857
SVOK	0.855
KC	0.851

10 Most Negative Correlations
NETE	-0.961
MMAC	-0.934
RAVN	-0.907
AMRB	-0.891
BOCH	-0.89
SHSP	-0.867
SRAC	-0.837
LWAC	-0.819
DFFN	-0.806

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Eloxx Pharmaceuticals Inc Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-16.65

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-16.65

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1 526.00

FY	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1 378.77

Financial Reports:

No articles found.

Eloxx Pharmaceuticals Inc

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.